{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:51:56Z","timestamp":1790787116972,"version":"4.1.0"},"reference-count":20,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody. Here, we evaluate the functional and anatomical outcomes of faricimab treatment in patients with diabetic macular edema (DME) that was refractory to ranibizumab or aflibercept. Materials and Methods: We performed a retrospective, observational, consecutive-case study of patients who had DME that was refractory to treatment with ranibizumab or aflibercept and were treated with faricimab between July 2022 and January 2023 under a pro re nata regimen. All the participants were followed for \u22654 months after the initiation of faricimab. The primary outcome was a recurrence interval of \u226512 weeks, and the secondary outcomes were the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Results: We analyzed 18 eyes of 18 patients. The mean recurrence interval of previous anti-VEGF injection was 5.8 \u00b1 2.5 weeks, which was significantly extended to 10.8 \u00b1 4.9 weeks (p = 0.0005) by the switch to faricimab. Eight patients (44.4%) achieved a recurrence interval of \u226512 weeks. A history of subtenon injection of triamcinolone acetonide (p = 0.0034) and the presence of disorganization of the retinal inner layers (p = 0.0326) were found to be significantly associated with a recurrence interval of &lt;12 weeks. The mean BCVAs were 0.23 \u00b1 0.28 logMAR and 0.19 \u00b1 0.23 logMAR, and the mean CMTs were 473.8 \u00b1 222.0 \u00b5m and 381.3 \u00b1 219.4 \u00b5m at baseline and 4 months, respectively, but these changes were not statistically significant. None of the patients experienced serious adverse events. Conclusions: Faricimab may extend the treatment interval for patients with DME that is refractory to ranibizumab or aflibercept. DME previously treated with the subtenon injection of triamcinolone acetonide or associated with disorganization of the retinal inner layers may be less likely to be associated with a longer recurrence interval after switching to faricimab.<\/jats:p>","DOI":"10.3390\/medicina59061125","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:28:21Z","timestamp":1686533301000},"page":"1125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept"],"prefix":"10.3390","volume":"59","author":[{"given":"Hiromi","family":"Ohara","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomona","family":"Hiyama","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Sadahide","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Minamoto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-1864","authenticated-orcid":false,"given":"Yoshiaki","family":"Kiuchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Browning, D.J.; et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"The Diabetic Retinopathy Clinical Research Network, Elman, M.J., Aiello, L.P., Beck, R.W., Bressler, N.M., Bressler, S.B., Edwards, A.R., Ferris, F.L., Friedman, S.M., and Glassman, A.R. (2010). Faculty Opinions recommendation of Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 117, 1064\u20131077.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment A secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_5","first-page":"216","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes","volume":"105","author":"Pollack","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bjophthalmol-2019-315199","article-title":"Real-world management of treatment-na\u00efve diabetic macular oedema in Japan: Two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study","volume":"104","author":"Shimura","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/bjophthalmol-2017-310941","article-title":"Long-Term Outcomes with as-Needed Aflibercept in Diabetic Macular Oedema: 2-Year Outcomes of the Endurance Extension Study","volume":"102","author":"Wykoff","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: A review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for Treatment-Resistant Diabetic Macular Edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000475603","article-title":"Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema","volume":"238","author":"Noma","year":"2017","journal-title":"Ophthalmologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of Vitreous Inflammatory Factors with Diabetic Macular Edema","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0002-9394(01)01269-7","article-title":"Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema","volume":"133","author":"Funatsu","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes with Center-Involved Diabetic Macular Edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","article-title":"Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: The chartres study","volume":"38","author":"Santos","year":"2018","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1167\/iovs.09-4493","article-title":"Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema","volume":"52","author":"Pelosini","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:52:38Z","timestamp":1760125958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061125"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061125","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,11]]}}}